Introduction
Several professional societies have published recommendations for administering supplemental iron to neonates with risk factors for developing iron deficiency (Table 1) . [1] [2] [3] [4] [5] [6] Those guidelines primarily focus on premature neonates, but infants of diabetic mothers (IDM) and small-for-gestational-age neonates (SGA) are also at risk. [7] [8] [9] [10] Disagreements occur regarding when iron dosing should begin, and what the daily iron dose should be. Moreover, variations exist regarding whether iron dosing should be stopped after a red blood cell (RBC) transfusion, and how iron is dosed accompanying erythropoiesis-stimulating agents (ESA; erythropoietin or darbepoetin). In general, when best practices have not been clearly established, implementing a consistent approach reduces variability and can lower costs and improve outcomes. [11] [12] [13] Our recent pilot study suggested that about 17% of IDM, SGA, and VLBW premature neonates have biochemical iron deficiency at birth. 14 On that basis we speculated that some neonates could benefit from initiating iron well before the time recommended in any of the published guidelines. [1] [2] [3] [4] [5] [6] As a step toward the consensus-building needed to develop a system-wide consistent approach to iron dosing in our neonatal intensive care units (NICUs), we analyzed 10 years of Intermountain Healthcare practice data.
Materials and Methods
This was a retrospective project involving neonates cared for in the 10-year period between January 2006 and December 2015 in the perinatal intensive care units of Intermountain Healthcare. Patients admitted to a NICU with a diagnosis of IDM, SGA, or VLBW were studied, because these have been reported as risk factors for developing iron deficiency. [8] [9] [10] IDM was defined as a neonate whose mother had the diagnosis of either pregestational diabetes mellitus (type 1 or type 2) or gestational diabetes (diagnosed during pregnancy). SGA was defined as a neonate with a birth weight <10th% lower reference interval of the Intermountain Healthcare normative data. 15 VLBW premature was defined as a neonate with a birth weight <1500 g and ≤34 weeks gestation. We determined whether each patient had any enteral or parenteral iron supplementation during their hospital stay, and if so when the dosing was begun.
Electronic pharmacy and NICU records were used from the following perinatal NICUs of Intermountain Healthcare: McKay-Dee Hospital Center, Ogden; LDS Hospital, Salt Lake City; Intermountain Medical Center, Murray; Utah Valley Regional Medical Center, Provo; and Dixie Regional Medical Center, St George. Intermountain Healthcare is a not-for-profit health care system operating 18 hospitals with labor and delivery units in Utah and Idaho. This quality report was approved for publication by the Intermountain Healthcare Institutional Review Board. Waiver from individual parental consent was granted because this was a deidentified, data-only quality report with appropriate privacy protection.
De-identified data were obtained from the Intermountain Healthcare Enterprise Data Warehouse by an authorized Intermountain Healthcare data analyst (Vickie L. Baer) and entered into and stored in a password-protected database. The program used for data collection into the Warehouse was a modified subsystem of clinical workstation. Clinical workstation is a webbased electronic medical record application that stores demographic and clinical information, such as history, physical examination results, laboratory data, problem lists, and discharge summaries. 3M Company (St Paul, MN) approved the structure and definitions of all data points within the program. Chi square with Yates correction (GraphPad Software, Inc, La Jolla, CA) was used to assess whether withholding iron after transfusion was different in the first 30 days after birth versus beyond 30 days. It was also used to assess whether giving iron after starting an ESA was different in the first 30 days after birth versus beyond 30 days. P values <.05 were considered to be significant. Figure 1 shows the number of patients in this analysis.
Results
Only neonates who remained in the hospital ≥14 days after birth were included, because none of the guidelines (Table 1) recommend commencing iron before 14 days. Of 790 IDM, only 11.8% received any supplemental iron in the hospital. Of 1403 SGA neonates, 9.8% received iron, and of 1813 VLBW preterm neonates, 27.1% received iron. Figure 2 shows the day enteral iron was begun for the 722 IDM, SGA, and VLBW neonates who received any enteral iron dosing during their hospitalization. For all 3 groups, less than 20% of those who received supplemental iron had it started by day 14 (thus <20% were compliant with the World Review of Nutrition and Dietetics recommendations 5 ), 55% to 60% had the iron started by day 30 (and thus were compliant with the American Academy of Pediatrics guidelines 1 ) , and 82% to 88% had it started by 8 weeks (56 days) (and thus were compliant with the European Society of Paediatric Gastroenterology and Nutrition guidelines 3 ). The percentage of IDM, SGA, and VLBW neonates who received enteral iron dosing in the NICU changed during the 10-year period studied, as shown in Figure 3 . The trend was to give iron supplementation to lower percentages over this decade. Stopping enteral iron dosing after an RBC transfusion was an inconsistent practice, as shown in Table  2 . When supplemental iron was being administered on the day of a transfusion, iron dosing was stopped after 73% of transfusions. This was similar to whether the transfusion was given in the first 30 days (40 of 47 [85%] had iron dosing stopped) or after day 30 (53 of 76 [70%] had iron dosing stopped; P = .38). We were unable to find a pattern to explain this inconsistency other than individual physician preference. Inconsistency was present within each NICU over the 10 years reviewed.
The practice of ordering iron supplementation when ESAs were administered was also inconsistent, as shown in Table 3 . This was the case whether the ESA was given during the first 30 days or beyond 30 days following birth (P = .09). Inconsistency was present within each NICU over the 10 years reviewed. 
Discussion
Iron supplementation is a common NICU practice, and it should have a scientific evidence base. However, an evidence base is currently lacking, leading to inconsistent neonatal iron dosing recommendations by various professional societies. As examples, the World Review of Nutrition and Dietetics suggests initiating iron supplementation for preterm infants at 2 weeks of age, 5 the American Academy of Pediatrics at 1 month, 1 the Canadian Pediatric Society at 6 to 8 weeks, 2 and the European Society of Paediatric Gastroenterology and Nutrition at no later than 8 weeks. 3 Iron deficiency at critical periods of early postnatal brain development can have adverse neurodevelopmental consequences. 16, 17 However, too much enteral iron can have adverse effects as well, including emesis, diarrhea or constipation, or other abdominal distresses. 18 Also, free iron in the blood, not bound to transport proteins such as transferrin or lactoferrin, can be a potent oxidizing agent, potentially adding to oxidant damage of the lungs and retinas of preterm neonates. 19 It is a worthwhile goal to develop a personalized medicine practice, where each NICU patient receives iron supplementation at a time, dose, and preparation that is ideal for the needs of that individual. The relationship between early iron deficiency and permanent neurodevelopmental delays makes this goal particularly compelling. 3, 16, 17 However, at the present time it is unclear how we should identify the unique iron needs of each NICU patient. For instance, the tests used to assess individual iron needs require better definition, and means of serial monitoring with noninvasive and reliable methods must be developed. Using a consistent approach to iron dosing for NICU patients at risk for iron deficiency is superior to the present inconsistent situation that can cause frustrating variations, increased costs, and worse outcomes.
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As a step toward developing evidence-based iron dosing practices at Intermountain Healthcare, we analyzed 10 years of practice data from our multi-NICU system. We studied IDM, SGA, and VLBW neonates because these groups have been reported to be at risk for developing iron deficiency. [8] [9] [10] We focused on the day iron supplements were initiated, and the practices related to iron dosing after RBC transfusions and accompanying ESA administration. We found considerable variation in each aspect.
In developing guidelines acceptable to each of our NICUs, we were influenced by our recent finding of biochemical iron deficiency in 17% of the IDM, SGA, and VLBW neonates we screened at birth. 14 We are currently engaged in a much larger validating study to identify NICU patients with iron deficiency and to assess the pathogenesis. Meanwhile, for iron guideline development, we elected to adopt a modification of the recommendation of the World Review of Nutrition and Dietetics, which advocates starting iron supplementation at 2 weeks. 5 Our new guideline is to initiate enteral iron dosing for IDM, SGA, and VLBW neonates at 10 to 14 days if they are feeding >100 mL/kg/day, and to use intravenous dosing for any who are not feeding this amount by 14 days (see Supplemental Material, available online at http://journals.sagepub.com/home/gph). In this way, the IDM, SGA, and VLBW neonates in our NICU system should have iron supplements begun at or before the time recommended in one of the more aggressive international iron dosing guidelines. 5 Some Intermountain Healthcare neonatologists advocate withholding iron supplements for 2 weeks following each RBC transfusion to avoid iron overload from the iron in the donor red cells plus the enteral iron. Indeed, an elevation in serum ferritin can occur in neonates after multiple NICU transfusions. 20 However, transfusion-acquired iron overload occurs primarily in neonates with hemolytic disorders, 21 where iron from repeated transfusions is not eliminated and can substantially increase the total body iron content. In contrast, iron overload is not a common problem among neonates transfused on the basis of phlebotomy losses or external hemorrhage, because the transfused blood basically replaces the iron lost, and thus does not create an increasing body iron burden. In our present study, we found that enteral iron supplements were stopped after 73% of NICU transfusions. In formulating our new guidelines, we judged it reasonable to withhold supplemental iron after RBC transfusions in neonates with hemolytic disorders, but not after transfusions given for the anemia of phlebotomy losses or external hemorrhage (see Supplemental Material, available online at http://journals.sagepub.com/home/gph).
Iron supplementation can be given enterally or intravenously and various preparations are available for each. CosmoFer (intravenous iron dextran) is a lowmolecular-weight iron dextran that has been given to preterm neonates described in case reports and studies, with no adverse effects identified, and is Food and Drug Administration (FDA) approved in infants 4 months and older. [22] [23] [24] [25] However, iron dextran has an FDA black box warning due to its association with anaphylactic reactions. Intravenous iron sucrose (Venofer, Vifor International), may have safety advantages 25 and is the current intravenous iron preparation we use in the Primary Children's Hospital Hematology clinic (Yaish and colleagues, 2017, unpublished data). Iron sucrose is FDA approved in children ≥2 years of age. 25 Meta analyses and reviews suggest that iron supplements should be given to neonates treated with an ESA (erythropoietin or darbepoetin). 26, 27 We found that within 3 days after initiating ESA treatment only about one third of IDM, SGA, or VLBW neonates had supplemental iron ordered. ESAs will be less effective if iron deficiency develops. Moreover, aggravating iron deficiency by administering ESAs to neonates who already have biochemical iron deficiency 14 could divert iron required for brain development into erythropoiesis. 28 We recognize limitations of our study. First, our databases contain only in-patient information; thus, we cannot track iron dosing after hospital discharge. Although iron dosing can, and probably in many cases should, begin during the NICU stay, much of the iron dosing is in the outpatient setting. Second, our databases are limited regarding iron intake from iron-fortified formulas and human milk fortifiers; thus, what we report as enteral iron intake is a minimal estimate, including only the iron given as a medication. Third, our records were not sufficient to determine the exact doses of supplemental iron our neonates received, daily or in total. Fourth, the only enteral iron preparation we administered during this period was ferrous sulfate, but other preparations might have advantages. Similarly, the only intravenous iron preparation we administered during this period was iron dextran, but other preparations such as iron sucrose almost certainly have advantages. 25 Finally, we have no information regarding the adequacy of the iron we administered during this 10-year period to prevent iron deficiency, nor do we know whether any patients received iron in excess of their iron requirements or developed problems therefrom. Such information is essential to developing best-practice iron dosing, but this must await studies that randomize neonates to various iron treatment groups and report short-term as well as intermediate and long-term neurodevelopmental outcomes.
Until definitive studies have been conducted and reported, and until we can engage in a personalized medicine approach for iron dosing of each individual NICU patient, we maintain that adopting a consistent approach to iron dosing is better than continuing with our widely divergent dosing practices. [11] [12] [13] The Online Supplemental Material (available online at http://journals.sagepub.com/home/gph) contains the guidelines we agreed to use in the Intermountain Healthcare NICUs until evidence-based and personalized iron dosing is available from our own ongoing studies and/or from the studies of others.
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